Overview
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene, identified by the Cohen lab in 2015. In rodent models it improves insulin sensitivity, increases endurance capacity, attenuates diet-induced obesity, and modulates AMPK signaling. Human evidence is at the very beginning: small observational and dose-finding studies, plus mechanistic plasma-level work in exercising humans. There are no published Phase 2 efficacy RCTs for any clinical indication as of this entry's review date.
Mechanism
Translocates to the nucleus under metabolic stress and modulates nuclear gene expression — a rare example of mitochondrial-to-nuclear retrograde signaling by a peptide. Activates AMPK, increases GLUT4 translocation in skeletal muscle, and modulates insulin signaling. Endogenous plasma MOTS-c declines with age and rises acutely with exercise.
Evidence by indication
We classify each indication separately. The same peptide can be Tier 1 for one use and Tier 4 for another. Tiers reflect the published literature, not the strength of community framing.
Insulin sensitivity / metabolic health
Multiple rodent studies (Lee et al. Cell Metabolism 2015 and follow-ons) show improved insulin sensitivity, attenuated diet-induced obesity, and improved glucose tolerance. One small human observational study correlates higher endogenous MOTS-c with better metabolic phenotypes, but no controlled exogenous-MOTS-c human RCT has tested the metabolic indication directly.
Exercise capacity / endurance
Rodent studies show MOTS-c administration improves endurance and exercise capacity in older mice (Reynolds et al. Nat Commun 2021). Human plasma-MOTS-c rises acutely with exercise, suggesting it's an exercise-responsive signaling peptide endogenously. No RCT has tested exogenous MOTS-c on human exercise endpoints.
Healthspan / longevity
Mitochondrial-derived peptides are an active longevity-research area. The strongest data is mechanistic and animal-model. No human longevity outcome data exist for MOTS-c. The claim 'MOTS-c extends healthspan in humans' is not supported by published evidence.
Mitochondrial dysfunction / mitochondrial disease
No published trials in mitochondrial disease populations. Mechanistic relevance is plausible but not validated. Anecdotal use exists in the rare-disease community but is not supported by primary literature.
No primary citations are anchored to this indication — the tier reflects the absence of usable literature, not a missing reference.
Studied dose ranges
The ranges below come from published trial protocols where available, and from documented self-experimenter consensus where the literature does not include human dose-finding work. The notes flag which is which.
Self-experimenter doses commonly cluster at 5–10 mg per injection, 2–3× weekly, extrapolated from animal-to-human dose conversions. These ranges are NOT derived from human dose-finding RCTs. Treat as approximate. Note 5 mg = 5,000 mcg; verify with the calculator.
Contraindications
- Pregnancy and breastfeeding (no human safety data)
- Active malignancy (no human oncology data; mitochondrial-signaling effects in cancer are an active research question)
- Hypersensitivity to peptide excipients
- Long-term use beyond ~12 weeks lacks any human safety characterization
- Any use should be considered experimental; not available through any FDA-approved channel
Reported side effects
- Injection site reactions
- Fatigue or transient flu-like symptoms reported anecdotally
- Possible transient hypoglycemia given the AMPK/insulin-sensitivity mechanism (theoretical; monitor in users with diabetes)
- No characterized long-term human side-effect profile — flag explicitly
Reconstitution & storage
Lyophilized powder reconstituted with bacteriostatic water. A 10 mg vial in 2 mL BAC water = 5 mg/mL, so a 5 mg dose ≈ 1 mL = 100 units on a U-100 syringe. (Note: a 5 mg dose nearly fills a U-100 syringe — most users prefer either a smaller dose or a higher dilution.) Use the calculator to verify.
Storage. Lyophilized: refrigerate 2–8 °C; protect from light. Reconstituted: refrigerate 2–8 °C, use within 30 days based on general peptide stability data — no MOTS-c-specific stability study published.
Open the peptide calculator → to compute exact draw volumes for your specific vial and BAC water choice.
Editorial note
DRAFT — pending Wayne's review. MOTS-c is a fascinating biology story (mitochondrial-encoded peptide, retrograde signaling) and that's exactly the kind of narrative that gets ahead of evidence. Hold the line at Tier 3 for everything — the rodent work is real, the human work is preliminary, and there are no Phase 2 efficacy RCTs. Re-tier when one publishes.
Citations
- [1]The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistanceLee C, Zeng J, Drew BG, et al. · Cell Metabolism · 2015 · PMID 25738459Foundational rodent metabolic-effect paper; primary anchor for the metabolic and longevity Tier 3 indications.View source
- [2]MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasisReynolds JC, Lai RW, Woodhead JST, et al. · Nature Communications · 2021 · PMID 33514812Rodent endurance/exercise capacity evidence; anchor for the exercise indication.View source
- [3]Mitochondrial-derived peptides are down-regulated in diabetes subjectsRamanjaneya M, Bettahi I, Jerobin J, et al. · European Journal of Endocrinology · 2019 · PMID 30940803Human observational data linking endogenous MOTS-c to metabolic phenotype; provides indirect human relevance.View source